Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review

ABSTRACT

A systematic review of published articles based on randomized clinical trials was conducted to ascertain the efficacy or perspective of using CAR-T cell therapy for refractory multiple myeloma. The PubMed database was searched with the combination of terms “multiple myeloma”, “refractory multiple myeloma”, “CAR T-cell”, and the PRISMA criteria were followed. Of the 78 articles found, only 5 were selected. The studies used different treatment protocols and four different types of CAR-T cells. All studies obtained interesting results in terms of increased progression-free survival and negative minimal residual disease responses. Some authors detected an expansion of CAR-T cells and noted dose-dependent relationship between treatment effectiveness and serum BCMA levels. Although the results were promising, a small number of patients still relapsed a few months after CAR-T cell infusion. Therefore, this new line of therapy should be further investigated, as it significantly increases progression-free survival and improves quality of life.

RESUMO

Uma revisão sistemática de artigos publicados com base em ensaios clínicos randomizados foi realizada para verificar a eficácia ou perspectiva do uso da terapia com células CAR-T para mieloma múltiplo refratário. Foi pesquisada a base de dados PubMed com a combinação dos termos “multiple myeloma”, “refratory multiple myeloma”, “CAR T-cell” e foram seguidos os critérios PRISMA. Dos 78 artigos encontrados, apenas 5 foram selecionados. Os estudos utilizaram diferentes protocolos de tratamento e quatro tipos diferentes de células CAR-T. Todos os estudos obtiveram resultados interessantes em termos de aumento da sobrevida livre de progressão e respostas negativas à doença residual mínima. Alguns autores detectaram uma expansão das células CAR-T e observaram uma relação dose-dependente entre a eficácia do tratamento e os níveis séricos de BCMA. Embora os resultados tenham sido promissores, um pequeno número de pacientes ainda apresentou recaída alguns meses após a infusão de células CAR-T. Portanto, esta nova linha de terapia deve ser mais investigada, pois aumenta significativamente a sobrevida livre de progressão e melhora a qualidade de vida.

Keywords:

Multiple myeloma - Immunotherapy, Adoptive - B-cell maturation antigen - Recurrence

Descritores:

Mieloma múltiplo - Imunoterapia adotiva - Antígeno de maturação de células B - Recorrência

Publikationsverlauf

Eingereicht: 21. Dezember 2023

Angenommen: 25. Januar 2024

Artikel online veröffentlicht:
25. Januar 2024

• REFERENCES

• 1 Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 93 (08) 981-1114
• 2 Ria R, Vacca A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int J Mol Sci 2020; 21 (02) 613
• 3 Tang F, Lu Y, Ge Y, Shang J, Zhu X. Infusion of chimeric antigen receptor T-cells against dual targets of CD19 and B cell maturation antigen for the treatment of refractory Multiple Myeloma. J Int Med Res 2020; Jan 48 (01) 1-7
• 4 Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91 (01) 101-19
• 5 Pinto V, Bergantim R, Caires HR, Seca H, Guimarães J, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers 2020; 12 (02) 407
• 6 Roshal M. Minimal residual disease detection by flow cytometry in multiple myeloma: why and how?. Semin Hematol 2018; Jan 55 (01) 4-12
• 7 Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018; Dec 11 (01) 141
• 8 Lee J, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res 2020; Jul 55 Suppl 1 S43-S53
• 9 Chim CS, Kumar SK, Orlowski RZ, Richardson PG, Gertz MA, Giralt S. et al. Management of relapsed and refractory Multiple Myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 2018; Feb 32 (02) 252-62
• 10 Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen on relapsed/refractory multiple myeloma. PNAS license 2019; 116 (19) 9543-51
• 11 Maples KT, Joseph NS, Harvey RD. Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther 2020; Sep 20 (12) 1021-35
• 12 Dempsey JL, Johns A, Rosko AE, Lazarus HM. The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 2019; May 20 (07) 887-902
• 13 Petty AJ, Heyman B, Yang Y. Chimeric antigen receptor cell therapy: overcoming obstacle to battle cancer. Cancers 2020; Mar 12 (04) 842
• 14 Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G. et al. CAR T-cell therapy in cancer: tribulations and road ahead. J Immunol Res 2020; Jan 2020: 1924379
• 15 Huang H, Wu HW, Hu YX. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ Sci B 2020; 21 (01) 29-41
• 16 Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019; May 380 (18) 1726-37
• 17 Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N. et al. T cells genetically modified to express an anti B cell maturation antigen chimeric antigen receptor causes remissions of poor prognosis relapsed Multiple Myeloma. J Clin Oncol 2018; Aug 36 (22) 2267-79
• 18 Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systemic review and meta-analyses: the PRISMA statement. PLoS Med 2009; Jul 6 (07) e1000097
• 19 Barbosa TF, Lira AB, Neto OBO, Santos LL, Santos IO, Barbosa LT. et al. Tutorial para execução de revisões sistemáticas e metanálises com estudos de intervenção em anestesia. Rev Bras Anestesiol 2018; May/Jun 69 (03) 299-306
• 20 Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
• 21 Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y. et al. A combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 2019; Oct 6 (10) E521-E9
• 22 U.S. Department of Health and Human Service (US), National Institutes of Health (NIH), National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [internet]. Washington: U.S. Department of Health and Human Service; 2009. May; [access in 2023 Dec 09]. Available from https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf
• 23 Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; Jul 124 (02) 188-95
• 24 Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL. et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol 2018; Jan 15 (01) 47-62
• 25 Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol 2018; 9: 1821
• 26 Cohen AD, Garfall AL, Stadmauer EA, Melenhorst JJ, Lacey SF, Lancaster E. et al. B cell maturation antigenspecific CAR T cells are clinically active in multiple myeloma. J Clin Invest 2019; Mar 129 (06) 2210-21
• 27 Caraccio C, Krishna S, Philips DJ, Schürch CM. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials and future directions. Front Immunol 2020; Apr 11: 501
• 28 Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC. et al. BMCA-targeting therapy: driving a new era of immunotherapy of multiple mieloma. Cancers (Basel) 2020; Jun 12 (06) 1473
• 29 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A. et al. The Society for Immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020; Jul 8 (02) e000734
• 30 Radhakrishnan S, Luetkens T, Scherer SD, Davis P, Mause ERV, Olson ML. et al. CD229 CAR T-cell eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun 2020; Feb 11 (01) 798